期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 127, 期 5, 页码 1646-1650出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI85504
关键词
-
资金
- BrightFocus Foundation [A2012070, R01 MH102364]
- National Eye Institute [5T32EY017203]
- National Science Foundation (NSF) [1232825]
- Direct For Education and Human Resources
- Division Of Graduate Education [1232825] Funding Source: National Science Foundation
Accumulation of amyloid-beta (A beta) protein may cause synapse degeneration and cognitive impairment in Alzheimer's disease (AD) by reactivating expression of the developmental synapse repressor protein Ephexin5 (also known as ARHGEF15). Here, we have reported that A beta is sufficient to acutely promote the production of Ephexin5 in mature hippocampal neurons and in mice expressing human amyloid precursor protein (hAPP mice), a model for familial AD that produces high brain levels of A beta. Ephexin5 expression was highly elevated in the hippocampi of human AD patients, indicating its potential relevance to AD. We also observed elevated Ephexin5 expression in the hippocampi of hAPP mice. Removal of Ephexin5 expression eliminated hippocampal dendritic spine loss and rescued AD-associated behavioral deficits in the hAPP mice. Furthermore, selective reduction of Ephexin5 expression using shRNA in the dentate gyrus of presymptomatic adolescent hAPP mice was sufficient to protect these mice from developing cognitive impairment. Thus, pathological elevation of Ephexin5 expression critically drives A beta-induced memory impairment, and strategies aimed at reducing Ephexin5 levels may represent an effective approach to treating AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据